Human immunoglobulin is normal for injection. The healing properties of human immunoglobulin

Instructions for use Human immunoglobulin normal
Buy Human immunoglobulin normal solution d/i i/v 25ml
Dosage forms
solution for intravenous administration, solution for intravenous injection, solution for infusion
Manufacturers
Microgen NPO (Nizhny Novgorod enterprise for the production of bacterial preparations-Imbio) (Russia), Microgen NPO (Khabarovsk enterprise for the production of bacterial preparations) (Russia),
Group
Immunoglobulins
Compound
Active ingredient: Normal human immunoglobulin.
Pharmacological action
Immunostimulating. Increases the level of antibodies in the body. With intravenous infusion, bioavailability is 100%. Redistribution of the drug occurs between the plasma and the extravascular space, and equilibrium is reached after approximately 7 days. In individuals with normal serum IgG levels, the biological half-life averages 21 days, while in patients with primary hypo- or agammaglobulinemia it is 32 days. Contains a wide range of opsonizing and neutralizing antibodies against bacteria, viruses and other pathogens. In patients suffering from primary or secondary immunodeficiency syndromes, it provides replenishment of missing IgG antibodies, which reduces the risk of infection.
Indications for use
Replacement therapy for the prevention of infections in primary immunodeficiency syndromes: agammaglobulinemia, common variable immunodeficiencies associated with a- or hypogammaglobulinemia; deficiency of IgG subclasses, replacement therapy to prevent infections in secondary immunodeficiency syndrome caused by chronic lymphocytic leukemia, AIDS in children or bone marrow transplantation, idiopathic thrombocytopenic purpura, Kawasaki syndrome (in addition to treatment with acetylsalicylic acid), severe bacterial infections, including sepsis (in combinations with antibiotics) and viral infections, prevention of infections in premature infants with low birth weight (less than 1500 g), Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, autoimmune neutropenia, partial red cell aplasia of hematopoiesis, thrombocytopenia of immune origin, incl. h. post-transfusion purpura, isoimmune thrombocytopenia of newborns, hemophilia caused by the formation of antibodies to coagulation factors, myasthenia gravis, prevention and treatment of infections during therapy with cytostatics and immunosuppressants, prevention of recurrent miscarriage.
Contraindications
During the first day after administration of the drug, a slight increase in body temperature and allergic reactions are possible. Sometimes headache, dizziness, dyspeptic symptoms, arterial hypo- or hypertension, tachycardia, and shortness of breath occur. In extremely rare cases, due to individual intolerance, anaphylactic reactions may develop. Hypersensitivity to human immunoglobulins, especially in patients with IgA deficiency due to the formation of antibodies to it.
Side effect
Headache, nausea, dizziness, vomiting, abdominal pain, diarrhea, arterial hypo- or hypertension, tachycardia, cyanosis, shortness of breath, feeling of constriction or pain in the chest, allergic reactions; rarely - severe hypotension, collapse, loss of consciousness, hyperthermia, chills, increased sweating, fatigue, malaise, back pain, myalgia, numbness, hot flashes or a feeling of cold.
Interaction
Transfusion therapy with intravenous immunoglobulin can be combined with other drugs, in particular antibiotics. The introduction of immunoglobulins can weaken (for 1.5-3 months) the effect of live vaccines against viral diseases such as measles, rubella, mumps and chicken pox (vaccinations with these vaccines should be carried out no earlier than 3 months later). After the administration of large doses of immunoglobulin, its effect can last in some cases up to one year. Do not use simultaneously with calcium gluconate in infants.
Directions for use and dosage
IV, drip. The dosage regimen is set individually, depending on the indications, the severity of the disease, the state of the immune system, and individual tolerance. For primary and secondary immunodeficiency syndromes, a single dose is 0.2-0.8 g/kg (on average 0.4 g/kg); administered at intervals of 2-4 weeks (to maintain minimum plasma IgG levels of 5 g/l). To prevent infections in patients undergoing bone marrow allotransplantation, 0.5 g/kg once 7 days before transplantation, and then once a week for the first 3 months after transplantation, and once a month for the next 9 months. For idiopathic thrombocytopenic purpura - 0.4 g/kg for 5 days in a row; in the future (if necessary) - 0.4 g/kg at intervals of 1-4 weeks to maintain normal platelet levels. For Kawasaki syndrome - 0.6-2 g/kg in several doses over 2-4 days. For severe bacterial infections (including sepsis) and viral infections - 0.4-1 g/kg daily for 1-4 days. To prevent infections in premature infants with low birth weight - 0.5-1 g/kg with an interval of 1-2 weeks. For Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy - 0.4 g/kg for 5 days; if necessary, 5-day courses of treatment are repeated at intervals of 4 weeks.
Overdose
No data available.
Special instructions
For persons suffering from autoimmune diseases (blood diseases, connective tissue diseases, nephritis), the drug should be administered against the background of appropriate therapy. Immunoglobulin passes into breast milk and may help transfer protective antibodies to the newborn. After administration of the drug, the patient's condition should be monitored for at least 30 minutes. Antishock therapy must be available in the room where the drug is administered. When anaphylactoid reactions develop, antihistamines, glucocorticosteroids and adrenergic agonists are used. A temporary increase in the level of antibodies in the patient’s blood after the administration of immunoglobulin can cause false positive results of serological tests. The rate of intravenous administration should not be exceeded due to the possibility of developing collaptoid reactions.
Storage conditions
At a temperature of 2-8 °C. In the refrigerator (not recommended to freeze).

Name:

Immunoglobulin (Immunoglobulinum)

Pharmacological action:

The drug is an immunomodulatory and immunostimulating agent. Contains a large number of neutralizing and opsonizing antibodies, thanks to which it effectively resists viruses, bacteria and other pathogens. The drug also replenishes the number of missing IgG antibodies, thereby reducing the risk of infection in individuals with primary and secondary immunodeficiency. Immunoglobulin effectively replaces and replenishes natural antibodies in the patient's serum.

When administered intravenously, the bioavailability of the drug is 100%. A gradual redistribution of the active substance of the drug occurs between the extravascular space and human plasma. Equilibrium between these environments is achieved on average within 1 week.

Indications for use:

The drug is prescribed for replacement therapy if there is a need to replenish and replace natural antibodies.

Immunoglobulin is used to prevent infections in:

Agammaglobulinemia,

Bone marrow transplantation,

Primary and secondary immunodeficiency syndrome,

Chronic lymphocytic leukemia,

Variable immunodeficiency associated with agammaglobulinemia,

AIDS in children.

The drug is also used for:

Thrombocytopenic purpura of immune origin,

Severe bacterial infections such as sepsis (in combination with antibiotics),

Viral infections,

Prevention of various infectious diseases in premature infants,

Guillain-Barré syndrome,

Kawasaki syndrome (usually in combination with the standard diseases for this disease),

Neutropenia of autoimmune origin,

Chronic demyelinating polyneuropathy,

Hemolytic anemia of autoimmune origin,

Erythrocyte aplasia,

Thrombocytopenia of immune origin,

Hemophilia caused by the synthesis of antibodies to factor P,

Treatment of myasthenia gravis,

Prevention of recurrent miscarriage.

Method of application:

Immunoglobulin is administered intravenously by drip and intramuscularly. The dosage is prescribed strictly individually, taking into account the type and severity of the disease, the individual tolerance of the patient and the state of his immune system.

Adverse events:

If all recommendations for administration, dosage and precautions are followed when using the drug, then the presence of serious side effects is very rare. Symptoms may appear several hours or even days after administration. Side effects almost always disappear after stopping taking Immunoglobulin. The majority of side effects are associated with the high rate of drug infusion. By reducing the speed and temporarily stopping the intake, you can achieve the disappearance of most of the effects. In other cases, symptomatic therapy is necessary.

The effects are most likely to occur when you first take the drug: during the first hour. This could be a flu-like syndrome - malaise, chills, high body temperature, weakness, headache.

The following symptoms also occur:

Respiratory system (dry cough and shortness of breath),

Digestive system (nausea, diarrhea, vomiting, stomach pain and increased salivation),

cardiovascular system (cyanosis, tachycardia, chest pain, flushing of the face),

Central nervous system (drowsiness, weakness, rarely symptoms of aseptic meningitis - nausea, vomiting, headache, photosensitivity, impaired consciousness, stiff neck),

Kidney (rarely acute tubular necrosis, worsening renal failure in patients with impaired renal function).

Allergic (itching, bronchospasm, skin rash) and local (redness at the site of intramuscular injection) reactions are also possible. Other side effects include: myalgia, aching joints, back pain, hiccups and sweating.

In very rare cases, collapse, loss of consciousness and severe hypertension have been observed. In these severe cases, discontinuation of the drug is necessary. It is also possible to administer antihistamines, adrenaline and plasma replacement solutions.

Contraindications:

The drug should not be used for:

Hypersensitivity to human immunoglobulins,

IgA deficiency due to the presence of antibodies to it,

Kidney failure

Exacerbation of the allergic process,

Diabetes mellitus

Anaphylactic shock to blood products.

The drug should be used with caution in case of migraine, pregnancy and lactation, and decompensated chronic heart failure. Also, if there are diseases in the genesis of which immunopathological mechanisms are the main ones (nephritis, collagenosis, immune blood diseases), then the drug should be prescribed with caution after the conclusion of a specialist.

During pregnancy:

There have been no studies on the effect of the drug on pregnant women. There is no information about the dangers of Immunoglobulin during pregnancy and lactation. But during pregnancy, this drug is administered in case of emergency, when the benefit of the drug significantly outweighs the possible risk to the child.

The drug should be used with caution during lactation: it is known that it penetrates into mother's milk and promotes the transfer of protective antibodies to the infant.

Interaction with other drugs:

The drug is pharmaceutically incompatible with other drugs. It should not be mixed with other drugs; a separate dropper should always be used for infusion. When using Immunoglobulin simultaneously with active immunization agents for viral diseases such as rubella, chicken pox, measles, and mumps, the effectiveness of treatment may decrease. If parenteral use of live viral vaccines is necessary, they can be used at least 1 month after taking Immunoglobulin. A more desirable waiting period is 3 months. If a large dose of Immunoglobulin is administered, its effect can last for a year. Also, this drug should not be used together with calcium gluconate in infants. There are suspicions that this will lead to negative phenomena.

Overdose:

Symptoms of overdose may appear with intravenous administration of the drug - increased blood viscosity and hypervolemia. This is especially true for people who are elderly or have impaired renal function.

Release form of the drug:

The drug is available in two forms: lyophilized dry powder for infusion (IV administration), solution for IM injection.

Storage conditions:

The drug must be stored in a warm, dark place. The storage temperature should be 2-10°C; the medicine should not be frozen. The shelf life will be indicated on the packaging. After this period, the drug cannot be used.

Synonyms:

Immunoglobin, Imogam-RAJ, Intraglobin, Pentaglobin, Sandoglobin, Cytopect, Human normal immunoglobulin, Human antistaphylococcal immunoglobulin, Human tick-borne encephalitis immunoglobulin liquid, Human tetanus immunoglobulin, Venoglobulin, Imbiogam, Imbioglobulin, Human normal immunoglobulin (Immuno globulinum Humanum Normale), Sandoglobulin, Cytotect, Humaglobin, Octagam, Intraglobin, Endobulin S/D

Compound:

The active substance of the drug is the immunoglobulin fraction. It was isolated from human plasma and then purified and concentrated. Immunoglobulin does not contain antibodies to hepatitis C viruses and human immunodeficiency, it does not contain antibiotics.

Additionally:

The drug should be used only as prescribed by a doctor. Do not use Immunoglobulin in damaged containers. If the transparency of the solution changes, flakes and suspended particles appear, then such a solution is unsuitable for use. When opening the container, the contents must be used immediately, since the already dissolved drug cannot be stored.

The protective effect of this drug begins to appear one day after administration, its duration is 30 days. In patients prone to migraines or with impaired renal function, increased caution should be exercised. You should also know that after using Immunoglobulin, there is a passive increase in the amount of antibodies in the blood. In serological testing, this may lead to false interpretation of the results.

The medicine is dispensed from pharmacies according to a doctor's prescription.

Drugs with similar effects:

ADT-anatoxinum / ADT-M-anatoxinum Derinat (solution for external use) (Derinat) Derinat (solution for injection) (Derinat) Licopid (Licopid) Neovir (Neovir)

Dear doctors!

If you have experience in prescribing this drug to your patients, share the result (leave a comment)! Did this medicine help the patient, did any side effects occur during treatment? Your experience will be of interest to both your colleagues and patients.

Dear patients!

If you were prescribed this medicine and completed a course of therapy, tell us whether it was effective (helped), whether there were any side effects, what you liked/disliked. Thousands of people search the Internet for reviews of various medications. But only a few leave them. If you personally do not leave a review on this topic, others will have nothing to read.

Thank you very much!

Immunobiological agent, highly purified polyvalent human immunoglobulin. Immunoglobulin contains about 90% monomeric IgG and a small fraction of decomposition products, dimeric and polymeric IgG and IgA, IgM in trace concentrations. The distribution of IgG subclasses in it corresponds to their fractional distribution in human serum. It has a wide range of opsonizing and neutralizing antibodies against bacteria, viruses and other pathogens. In patients with primary or secondary immunodeficiency syndromes, it provides replenishment of missing IgG class antibodies, which reduces the risk of developing infection. In some other immune disorders, such as idiopathic (immune origin) thrombocytopenic purpura and Kawasaki syndrome, the mechanism of clinical effectiveness of immunoglobulin is not entirely clear.
After IV infusion, a redistribution of immunoglobulin occurs between the blood plasma and the extravascular space, and equilibrium is achieved after approximately 7 days. Antibodies present in exogenous immunoglobulin have the same pharmacokinetic characteristics as antibodies in endogenous IgG. In individuals with normal serum IgG levels, the biological half-life of immunoglobulin averages 21 days, while in patients with primary hypogammaglobulinemia or agammaglobulinemia, the half-life of total IgG averages 32 days (however, there is significant individual variation that may be important when establishing a dosage regimen for a particular patient).

Indications for use of the drug Human immunoglobulin

Replacement therapy for the prevention of infections in primary immunodeficiency syndrome: agammaglobulinemia, common variable immunodeficiencies caused by agammaglobulinemia or hypogammaglobulinemia, deficiency of IgG subclasses;
replacement therapy to prevent infections in secondary immunodeficiency syndrome caused by chronic lymphocytic leukemia, AIDS in children, bone marrow transplantation;
idiopathic (immune origin) thrombocytopenic purpura;
Kawasaki syndrome (usually as an adjunct to standard treatment with acetylsalicylic acid);
severe bacterial infections, including sepsis (in combination with antibiotics), and viral infections;
prevention of infections in premature infants with low birth weight (less than 1500 g);
Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy;
neutropenia of autoimmune origin and autoimmune hemolytic anemia;
true red cell aplasia mediated through antibodies;
thrombocytopenia of immune origin, for example post-infusion purpura or isoimmune thrombocytopenia of newborns;
hemophilia caused by the formation of antibodies to factor P;
treatment of myasthenia gravis;
prevention and treatment of infections during therapy with cytostatics and immunosuppressants;
prevention of recurrent miscarriage.

Use of the drug Human immunoglobulin

IV drip. The regimen of use is determined individually, taking into account the indications, severity of the disease, the state of the patient’s immune system and individual tolerance. The dosage regimens given below are advisory in nature.
For primary immunodeficiency syndromes, a single dose is 200-800 mg/kg (average 400 mg/kg). Administered at intervals of 3-4 weeks to achieve and maintain a minimum level of IgG in the blood plasma of at least 5 g/l.
For secondary immunodeficiency syndromes, a single dose is 200-400 mg/kg. Administer at intervals of 3-4 weeks.
For the prevention of infections in patients undergoing bone marrow allotransplantation , The recommended dose is 500 mg/kg. It can be administered once 7 days before transplantation and then repeated once a week for the first 3 months after transplantation and once a month for the next 9 months.
For idiopathic thrombocytopenic purpura, an initial single dose of 400 mg/kg is prescribed, administered for 5 consecutive days. It is possible to prescribe a total dose of 0.4-1 g/kg once or over 2 consecutive days. If necessary, further doses of 400 mg/kg can be administered at intervals of 1-4 weeks to maintain a sufficient platelet count.
For Kawasaki syndrome, 0.6-2 g/kg is administered in several doses over 2-4 days.
For bacterial infections (including sepsis) and viral infections, 0.4-1 g/kg is administered daily for 1-4 days.
To prevent infection in premature infants with low birth weight, 0.5-1 g/kg is administered at intervals of 1-2 weeks.
For Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, 0.4 g/kg is administered for 5 consecutive days.
If necessary, 5-day courses of treatment are repeated at intervals of 4 weeks.
Depending on the specific situation, the lyophilized powder can be dissolved in 0.9% sodium chloride solution, water for injection or 5% glucose solution. The concentration of immunoglobulin in any of these solutions can vary from 3 to 12% depending on the volume used.
For patients receiving immunoglobulin for the first time, it is recommended to administer it in the form of a 3% solution, and the initial infusion rate should be from 0.5 to 1 ml/min. If there are no side effects during the first 15 minutes, the infusion rate can be gradually increased to 2.5 ml/min. For patients who regularly receive and tolerate immunoglobulin, it can be administered in higher concentrations (up to 12%), but the initial infusion rate should be low. If there are no side effects, the infusion rate can be gradually increased.

Contraindications to the use of the drug Human immunoglobulin

Increased sensitivity to human immunoglobulins, especially in patients with IgA deficiency due to the presence of antibodies to IgA.

Side effects of the drug Human immunoglobulin

more likely during the first infusion; occur soon after the start of the infusion or during the first 30-60 minutes.
From the side of the central nervous system: possible headache, nausea; less often - dizziness.
From the digestive tract: in rare cases - vomiting, abdominal pain, diarrhea.
From the cardiovascular system: rarely — arterial hypotension or hypertension (arterial hypertension), tachycardia, feeling of constriction or chest pain, cyanosis, shortness of breath.
Allergic reactions: very rarely, severe arterial hypotension, collapse and loss of consciousness have been observed.
Other: possible hyperthermia, chills, increased sweating and fatigue, malaise; rarely - back pain, myalgia; numbness, hot flashes, or cold sensation.

Special instructions for the use of the drug Human immunoglobulin

Immunoglobulin is obtained from the blood plasma of healthy donors who, according to clinical examination, laboratory blood tests, and medical history, have no evidence of transfusion-transmitted infections or blood-derived drugs.
If severe side effects occur (severe arterial hypotension, collapse), the infusion should be stopped; IV administration of adrenaline, corticosteroids, antihistamines and plasma expanders may be indicated. Patients with agammaglobulinemia or severe hypogammaglobulinemia who have never received immunoglobulin replacement therapy or have received such therapy more than 8 weeks ago have an increased risk of developing hypersensitivity reactions (including anaphylactic shock) when administered by rapid intravenous infusion. Therefore, rapid infusion is not recommended for these patients and should be closely monitored throughout the infusion period. A transient increase in creatinine levels has been reported after administration of immunoglobulin to patients with impaired renal function caused by an underlying disease (diabetes mellitus, systemic lupus erythematosus). In such patients, serum creatinine levels should be monitored for 3 days after infusion.
After the administration of immunoglobulin, a passive increase in the level of antibodies in the patient’s blood may be observed, which can lead to an erroneous false-positive interpretation of the results of serological testing.
Although there are no reports of adverse effects on the fetus or reproductive capacity, immunoglobulin should be used in pregnant women only when clearly needed.

Drug interactions Human immunoglobulin

Concomitant use of immunoglobulin may reduce the effectiveness of active immunization against measles, rubella, mumps and varicella. In this regard, live viral vaccines for parenteral use should not be used for 6 weeks to 3 months after the use of immunoglobulin. In case of repeated administration in doses from 400 mg to 1 g/kg in children with idiopathic thrombocytopenic purpura or other pathology, vaccination against epidemic hepatitis should be postponed for 8 months. Immunoglobulin should not be mixed in the same volume with any other medications.

Overdose of the drug Human immunoglobulin, symptoms and treatment

Not described.

List of pharmacies where you can buy Human Immunoglobulin:

Saint Petersburg

Replacement therapy for the prevention of infections in primary immunodeficiency syndromes: agammaglobulinemia, common variable immunodeficiencies associated with a- or hypogammaglobulinemia; deficiency of IgG subclasses, replacement therapy to prevent infections in secondary immunodeficiency syndrome caused by chronic lymphocytic leukemia, AIDS in children or bone marrow transplantation, idiopathic thrombocytopenic purpura, Kawasaki syndrome (in addition to treatment with acetylsalicylic acid), severe bacterial infections, including sepsis (in combinations with antibiotics) and viral infections, prevention of infections in premature infants with low birth weight (less than 1500 g), Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, autoimmune neutropenia, partial red cell aplasia of hematopoiesis, thrombocytopenia of immune origin, incl. h. post-transfusion purpura, isoimmune thrombocytopenia of newborns, hemophilia caused by the formation of antibodies to coagulation factors, myasthenia gravis, prevention and treatment of infections during therapy with cytostatics and immunosuppressants, prevention of recurrent miscarriage.

Contraindications Human immunoglobulin normal solution for intramuscular injection 1.5ml/dose 1 dose

During the first day after administration of the drug, a slight increase in body temperature and allergic reactions are possible. Sometimes headache, dizziness, dyspeptic symptoms, arterial hypo- or hypertension, tachycardia, and shortness of breath occur. In extremely rare cases, due to individual intolerance, anaphylactic reactions may develop. Hypersensitivity to human immunoglobulins, especially in patients with IgA deficiency due to the formation of antibodies to it.

Method of administration and dosage Human immunoglobulin normal solution for intramuscular injection 1.5 ml/dose 1 dose

IV, drip. The dosage regimen is set individually, depending on the indications, the severity of the disease, the state of the immune system, and individual tolerance. For primary and secondary immunodeficiency syndromes, a single dose is 0.2-0.8 g/kg (on average 0.4 g/kg); administered at intervals of 2-4 weeks (to maintain minimum plasma IgG levels of 5 g/l). To prevent infections in patients undergoing bone marrow allotransplantation, 0.5 g/kg once 7 days before transplantation, and then once a week for the first 3 months after transplantation, and once a month for the next 9 months. For idiopathic thrombocytopenic purpura - 0.4 g/kg for 5 days in a row; in the future (if necessary) - 0.4 g/kg at intervals of 1-4 weeks to maintain normal platelet levels. For Kawasaki syndrome - 0.6-2 g/kg in several doses over 2-4 days. For severe bacterial infections (including sepsis) and viral infections - 0.4-1 g/kg daily for 1-4 days. To prevent infections in premature infants with low birth weight - 0.5-1 g/kg with an interval of 1-2 weeks. For Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy - 0.4 g/kg for 5 days; if necessary, 5-day courses of treatment are repeated at intervals of 4 weeks.

Name:

Immunoglobulin (Immunoglobulinum)

Pharmacological
action:

The drug is immunomodulatory and immunostimulating agent. Contains a large number of neutralizing and opsonizing antibodies, thanks to which it effectively resists viruses, bacteria and other pathogens. Also the drug replenishes the number of missing IgG antibodies, thereby reducing the risk of infection in persons with primary and secondary immunodeficiency. Immunoglobulin effectively replaces and replenishes natural antibodies in the patient's serum.

When administered intravenously the bioavailability of the drug is 100%. A gradual redistribution of the active substance of the drug occurs between the extravascular space and human plasma. Equilibrium between these environments is achieved on average within 1 week.

Additionally:

The drug must be used only by doctor's prescription. Do not use Immunoglobulin in damaged containers. If the transparency of the solution changes, flakes and suspended particles appear, then such a solution is unsuitable for use. When opening the container, the contents must be used immediately, since the already dissolved drug cannot be stored.

The protective effect of this drug begins to appear 24 hours after administration, its duration is 30 days. In patients prone to migraines or with impaired renal function, increased caution should be exercised. You should also know that after using Immunoglobulin, there is a passive increase in the amount of antibodies in the blood. In serological testing, this may lead to false interpretation of the results.

Indications for
application:

The drug is prescribed for replacement therapy if there is a need to replenish and replace natural antibodies.

Immunoglobulin is used for the prevention of infections at:
- agammaglobulinemia;
- bone marrow transplantation;
- primary and secondary immunodeficiency syndrome;
- chronic lymphocytic leukemia;
- variable immunodeficiency associated with agammaglobulinemia;
- AIDS in children.

The drug is also used for:
- thrombocytopenic purpura of immune origin;
- severe bacterial infections such as sepsis (in combination with antibiotics);
- viral infections;
- prevention of various infectious diseases in premature infants;
- Guillain-Barre syndrome;
- Kawasaki syndrome (usually in combination with the standard diseases for this disease);
- neutropenia of autoimmune origin;
- chronic demyelinating polyneuropathy;
- hemolytic anemia of autoimmune origin;
- erythrocyte aplasia;
- thrombocytopenia of immune origin;
- hemophilia caused by the synthesis of antibodies to factor P;
- treatment of myasthenia gravis;
- prevention of recurrent miscarriage.

Directions for use:

Immunoglobulin is administered intravenously drip and intramuscularly. The dosage is prescribed strictly individually, taking into account the type and severity of the disease, the individual tolerance of the patient and the state of his immune system.

Side effects:

The effects are most likely to occur when you first take the drug: during the first hour. This could be a flu-like syndrome - malaise, chills, high body temperature, weakness, headache.

The following symptoms also occur:
- respiratory system(dry cough and shortness of breath);
- digestive system(nausea, diarrhea, vomiting, stomach pain and increased salivation);
cardiovascular system (cyanosis, tachycardia, chest pain, flushing of the face);
- central nervous system(drowsiness, weakness, rarely symptoms of aseptic meningitis - nausea, vomiting, headache, photosensitivity, impaired consciousness, stiff neck);
- kidney(rarely acute tubular necrosis, worsening renal failure in patients with impaired renal function).

Also possible allergic(itching, bronchospasm, skin rash) and local(hyperemia at the site of intramuscular injection) reactions. Other side effects include: myalgia, aching joints, back pain, hiccups and sweating.

In very rare cases collapse, loss of consciousness and severe hypertension were observed. In these severe cases, discontinuation of the drug is necessary. It is also possible to administer antihistamines, adrenaline and plasma replacement solutions.

Contraindications:

The drug should not be used when:
- hypersensitivity to human immunoglobulins;
- IgA deficiency due to the presence of antibodies to it;
- renal failure;
- exacerbation of the allergic process;
- diabetes mellitus;
- anaphylactic shock to blood products.

The drug should be used with caution for migraine, pregnancy and lactation, decompensated chronic heart failure. Also, if there are diseases in the genesis of which immunopathological mechanisms are the main ones (nephritis, collagenosis, immune blood diseases), then the drug should be prescribed with caution after the conclusion of a specialist.

Interaction with
other medicinal
by other means:

The drug is pharmaceutically incompatible with other drugs. It should not be mixed with other drugs; a separate dropper should always be used for infusion. When using Immunoglobulin simultaneously with active immunization agents for viral diseases such as rubella, chicken pox, measles, and mumps, the effectiveness of treatment may decrease. If parenteral use of live viral vaccines is necessary, they can be used at least 1 month after taking Immunoglobulin. A more desirable waiting period is 3 months. If a large dose of Immunoglobulin is administered, its effect can last for a year. Also, this drug should not be used together with calcium gluconate in infants. There are suspicions that this will lead to negative phenomena.